MIRUM PHARMACEUTICALS INC's ticker is MIRM and the CUSIP is 604749101. A total of 109 filers reported holding MIRUM PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $339,352 | +8.2% | 10,739 | -11.5% | 0.21% | +10.8% |
| Q2 2023 | $313,777 | -23.6% | 12,129 | -29.0% | 0.19% | -17.7% |
| Q1 2023 | $410,478 | +25.4% | 17,089 | +1.8% | 0.23% | +32.2% |
| Q4 2022 | $327,405 | +26.4% | 16,790 | +36.3% | 0.17% | +66.0% |
| Q3 2022 | $259,000 | +9.7% | 12,318 | +1.5% | 0.10% | +18.4% |
| Q2 2022 | $236,000 | -4.1% | 12,137 | +8.7% | 0.09% | -20.9% |
| Q1 2022 | $246,000 | +30.9% | 11,161 | -5.6% | 0.11% | +54.9% |
| Q4 2021 | $188,000 | -21.3% | 11,817 | -1.4% | 0.07% | -32.4% |
| Q3 2021 | $239,000 | +9.6% | 11,984 | -4.9% | 0.10% | +16.7% |
| Q2 2021 | $218,000 | -12.1% | 12,602 | +0.7% | 0.09% | -14.3% |
| Q1 2021 | $248,000 | +15.3% | 12,515 | +1.8% | 0.10% | +18.0% |
| Q4 2020 | $215,000 | -36.0% | 12,292 | -29.6% | 0.09% | -49.4% |
| Q3 2020 | $336,000 | -13.0% | 17,458 | -12.0% | 0.18% | -3.8% |
| Q2 2020 | $386,000 | – | 19,835 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 6,470,392 | $204,464,387 | 13.58% |
| NEA Management Company, LLC | 2,186,243 | $69,085,279 | 5.34% |
| TANG CAPITAL MANAGEMENT LLC | 1,137,107 | $35,932,581 | 5.07% |
| BOONE CAPITAL MANAGEMENT LLC | 389,791 | $12,317,396 | 3.89% |
| Highlander Partners, L.P. | 122,980 | $3,886,168 | 3.84% |
| BVF INC/IL | 4,370,024 | $138,092,758 | 3.72% |
| Prosight Management, LP | 353,508 | $11,170,853 | 3.54% |
| Novo Holdings A/S | 1,500,000 | $47,400,000 | 3.50% |
| Nicholas Investment Partners, LP | 1,199,366 | $37,899,966 | 2.83% |
| Eventide Asset Management | 3,958,579 | $125,091,097 | 2.25% |